Bharat Parenterals
- Market cap
- ₹ 1,141 Cr.
- P/E
- 50.8x
- P/B
- 3.8x
- 52-week range
- 1,125.7 – 2,277.6
- ROE
- −3%
- ROCE
- −2%
- Dividend yield
- 0.1%
- Debt / equity
- 0.45
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Bharat Parenterals Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing generic and specialty formulations. The Company offers a range of products, including antibiotics, anaesthetics, quinolones, antifungal, analgesic, antimalarial, cardiovascular system, central nervous system, gastrointestinal / alimentary system, erectile dysfunction, supplements, and steroids & hormones. The Company's subsidiaries include Innoxel Lifesciences Private Limited, Varenyam Biolifesciences Private Limited, and Varenyam Healthcare Private Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Bharat Parenterals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)50.8 against a typical 34.3: pricier than most peers (1st = cheapest).157th of 220
- Sales growth−19.2% against a typical +15.6% from a year earlier.175th of 197
- Size₹ 1,140.6 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).84th of 199
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 | 60 | 68 | 93 | 72 | 72 | 104 | 116 | 65 | 65 | 100 | 94 |
| Expenses | 55 | 53 | 67 | 88 | 79 | 69 | 102 | 102 | 64 | 63 | 100 | 85 |
| Operating Profit | 4 | 7 | 1 | 4 | −8 | 4 | 2 | 14 | 1 | 2 | −1 | 9 |
| OPM % | 7.2% | 11.1% | 1.5% | 4.9% | −10.7% | 5% | 2.1% | 11.9% | 1.3% | 2.7% | −0.5% | 9.1% |
| Other Income | 3 | 1 | 3 | 3 | 4 | 3 | 2 | 1 | 4 | 1 | 4 | 1 |
| Interest | 1 | 1 | 1 | 3 | 3 | 3 | 4 | 4 | 3 | 3 | 3 | 2 |
| Depreciation | 2 | 2 | 4 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 9 | 9 |
| Profit before tax | 5 | 5 | −1 | −5 | −15 | −6 | −8 | 3 | −7 | −8 | −8 | −2 |
| Tax % | 46.5% | 33.5% | 88.2% | 85.3% | 13.9% | 43% | 13.6% | 133.7% | 17.7% | 16.8% | −2.5% | 138% |
| Net Profit | 2 | 4 | −3 | −9 | −18 | −8 | −9 | −1 | −9 | −10 | −8 | −4 |
| EPS in Rs | 6.05 | 6.5 | −0.52 | 1.96 | −11.5 | −2.42 | −6.86 | 11.94 | −10.49 | −6.37 | −6.96 | 1.47 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 11%
- 5 Years
- 11%
- 3 Years
- 17%
- TTM
- −11%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- −172%
- 10 Years
- —
- 5 Years
- 28%
- 3 Years
- 31%
- TTM
- —
- 10 Years
- 7%
- 5 Years
- 3%
- 3 Years
- −1%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Bharat Parenterals | ₹ 1,923.00 | ₹ 1,141 Cr. | 50.8x | 3.8x | −3% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 39.5x | 5.7x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 78.8x | 12.3x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 74.5x | 19.7x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28.7x | 3.5x | — | 11.9% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 20.8x | 4.2x | 19.7% | 18.5% |
Management
- Bharatkumar Rameshchandra Desai
- Managing Director, Executive Chairman of the Board
- Jignesh Nitinchandra Shah
- Chief Financial Officer
- Sharmin Nareshkumar Soni
- Company Secretary and Compliance Officer
- Hemang Jayendrabhai Shah
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.